Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Oct 8;97(7):883-7.
doi: 10.1038/sj.bjc.6603987. Epub 2007 Sep 18.

Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up

D Genet  1 , C Lejeune, P Bonnier, Y Aubard, L Venat-Bouvet, D J Adjadj, J Martin, J L Labourey, A Benyoub, P Clavère, V Lebrun-Ly, P Juin, L Piana, N Tubiana-Mathieu
Affiliations

Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up

D Genet et al. Br J Cancer. .

Abstract

The aim of this study was to evaluate with a long follow-up the efficacy of concomitant chemoradiotherapy in non-metastatic inflammatory breast cancer (IBC) and to evaluate the breast conservation rate. Between 1990 and 2000, 66 non-metastatic patients with IBC were treated with chemotherapy and concomitant irradiation. The induction chemotherapy consisted of epirubicine, cyclophosphamide and vindesine, in association with split-course bi-fractionated irradiation to a total dose of 65 Gy with concomitant cisplatin and 5-fluorouracil. Maintenance chemotherapy consisted of high-dose methotrexate and six cycles of epirubicine, cyclophosphamide and fluorouracil. Hormonal treatment was given if indicated. Mastectomy was not systemic. Among 65 evaluable patients, 57 (87.6%) achieved a complete clinical response and had a breast conservation. Only six loco regional relapses were noted in six patients with a delay of 20 months and with concomitant metastatic dissemination in four cases. Median disease-free survival (DFS) was 28 months. Median overall survival (OS) was 63 months and median follow-up was 55.5 months. Induction chemotherapy and concomitant irradiation is feasible in patients with IBC, permitting a breast conservation with a high rate of local control with an OS comparable to that of the best recent series.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Induction treatment protocol plan. Three Cycles with 28 days delay.
Figure 2
Figure 2
Disease-free survival for all patients.
Figure 3
Figure 3
Overall Survival for all patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and non inflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21: 2254–2259 - PubMed
    1. Arriagada R, Mouriesse H, Spielmann M, Mezlini A, Oudinot P, le Chevalier T, Cuvier C, Fontaine F, Travagli JP, May-Levin F (1990) Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiat Oncol Biol Phys 19: 1207–1210 - PubMed
    1. Baldini E, Gardin G, Evagelista G, Prochilot T, Collecchi P, Lionetto R (2004) Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 5: 358–363 - PubMed
    1. Barker JL, Montague ED, Peters LJ (1980) Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 45: 625–629 - PubMed
    1. Bauer RL, Bush E, Levine E, Edge SB (1995) Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol 2: 288–294 - PubMed

MeSH terms